急性肾损伤的实用性研究:急性疾病质量倡议(ADQI)第19工作组共识报告
急性肾损伤(AKI)在中国及全球已成为重大医疗与经济负担,流行病学和发病机制认识虽有进展,但最佳诊疗尚无共识。急性疾病质量倡议(ADQI)第19次会议聚焦于在中国识别并设计相关且可行的AKI研究。工作组通过文献检索(MEDLINE数据库及相关文献书目)分析现有证据,并采用两步德尔菲法确定研究优先级、提出针对未满足需求的具体研究设计。结果在三个领域(AKI预防集束化治疗、AKI的肾脏替代治疗、液体管理)识别了重要知识缺口并提出实用性研究,同时讨论了用生物标志物指导临床试验。最终就聚焦中国实用性试验的AKI研究议程达成共识。
要点
- ADQI第19工作组通过两步德尔菲法确定AKI研究优先级,提出针对未满足需求的具体研究设计。
- 研究议程聚焦三大领域:AKI预防集束化治疗、AKI的肾脏替代治疗(RRT)、液体管理。
- 工作组识别了现有知识的重要缺口,并提出在上述三个领域开展实用性研究。
- 生物标志物用于指导临床试验也是讨论内容之一。
- 共识聚焦于中国的实用性试验,旨在填补AKI最佳诊疗缺乏共识的空白。
适用人群与场景
- 中国的急性肾损伤(AKI)患者(研究议程聚焦中国)。
研究设计与关键结果
- 研究类型:ADQI第19工作组共识报告;方法为文献检索(MEDLINE数据库及相关研究、综述文章书目)分析现有文献,并采用两步德尔菲法确定研究优先级、提出具体研究设计。
- 在三个领域识别了重要知识缺口并提出实用性研究:AKI预防集束化治疗、AKI的肾脏替代治疗(RRT)、液体管理。
- 讨论了使用生物标志物指导临床试验。
- 就聚焦中国实用性试验的AKI研究议程达成共识。
证据类型、等级与局限
- 证据类型:共识报告(ADQI第19工作组),采用两步德尔菲法。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐
指南或共识出处
- 急性疾病质量倡议(ADQI)第19工作组共识报告(J Crit Care)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Acute kidney injury (AKI) has become a major medical and financial burden in China along with the rest of the world. There have been considerable advances in the understanding of the epidemiology and pathogenesis of AKI. However, there is no consensus regarding the optimal care for patients. The Acute Disease Quality Initiative (ADQI) 19 meeting focused on identifying and designing relevant and achievable AKI-related studies in China.
MATERIALS & METHODS: The working group developed a list of preliminary questions and objectives and performed analysis of the existing literature. Relevant studies were identified through a literature search using the MEDLINE database and bibliographies of relevant research and review articles. We then used a two-step Delphi process to prioritize a research agenda and proposed specific study designs to address unmet needs.
RESULTS: Important gaps in existing knowledge were identified and pragmatic studies were proposed in three distinct areas: care bundles for AKI prevention, renal replacement therapy (RRT) for AKI, and fluid management. In addition, the use of biomarkers to guide clinical trials was discussed.
CONCLUSIONS: Consensus was reached on a research agenda for AKI with a specific focus on pragmatic trials in China.
参考来源
- Peng Z, Yu K, Ostermann M, et al. Pragmatic studies for acute kidney injury: Consensus report of the Acute Disease Quality Initiative (ADQI) 19 Workgroup. J Crit Care. 2017. PMID: 29274596. doi:10.1016/j.jcrc.2017.12.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。